Skip to main content

Search
Profile

Aaron K. Olson, MD

|
Aaron K. Olson, MD

Cardiology

On staff since July 2006

Academic Title: Assistant Professor, Division of Cardiology, Department of Pediatrics

Research Center: Center for Developmental Therapeutics

"I go to work each day striving to make new discoveries in the basic science mechanisms controlling cardiovascular disease in children. I hope to translate these discoveries into new therapies for pediatric patients. "

Overview

Board Certification(s)
Pediatrics
Pediatric Cardiology
Medical/Professional School
University of Minnesota , Minneapolis
University of Minnesota - Duluth School of Medicine, Duluth
Residency
Pediatrics, University of Chicago , Chicago
Fellowship
Pediatric Cardiology, University of Iowa Hospitals and Clinics, Iowa City
Pediatric Cardiology, University of Iowa Hospitals and Clinics, Iowa City
Clinical Interests

Neonatal heart disease

Lab URL

http://www.seattlechildrens.org/research/developmental-therapeutics/labs-programs/olson-lab/

Research Focus Area

Cardiac Metabolism, Kawasaki Disease, Cardiac Hypertrophy, Genetic Cardiovascular Disease

Publications

Prospective open-label trial of etanercept as adjunctive therapy for kawasaki disease.
The Journal of pediatrics , 2010 Dec: 960-966.e1
Triiodothyronine Supplementation in Infants and Children Undergoing Cardiopulmonary Bypass (TRICC): a multicenter placebo-controlled randomized trial: age analysis.
Circulation , 2010 Sep 14: S224-33
Triiodothyronine Supplementation in Infants and Children Undergoing Cardiopulmonary Bypass (TRICC): a multicenter placebo-controlled randomized trial: age analysis.
Circulation , 2010 Sep 14: S224-33
Prospective Open-Label Trial of Etanercept as Adjunctive Therapy for Kawasaki Disease.
The Journal of pediatrics , 2010 Jul 26
Superior cardiac function via anaplerotic pyruvate in the immature swine heart after cardiopulmonary bypass and reperfusion.
American journal of physiology. Heart and circulatory physiology , 2008 Dec: H2315-20
Cardioselective dominant-negative thyroid hormone receptor (Delta337T) modulates myocardial metabolism and contractile efficiency.
American journal of physiology. Endocrinology and metabolism , 2008 Aug: E420-7
Activation of the mitogen-activated protein kinases and Akt in response to pulmonary artery banding in the fetal sheep heart is developmentally regulated.
Neonatology , 2008: 145-52
The mitogen-activated protein kinases and Akt are developmentally regulated in the chronically anemic fetal sheep heart.
Journal of the Society for Gynecologic Investigation , 2006 Apr: 157-65
Mitogen-activated protein kinase activation and regulation in the pressure-loaded fetal ovine heart.
American journal of physiology. Heart and circulatory physiology , 2006 Apr: H1587-95

Presentations

Presentations TitleEventLocationDate
Metabolic Substrate Utilization During C-Myc Induced Cardiac HypertrophyJuly 1, 2009

Research Funding

Grant TitleGrantorAmountAward Date
The Marfan Trial- a Trial of Beta Blocker Therapy (Atenolol) vs. Angiotensin II Receptor Blocker Therapy (Losartan) in individuals with Marfan syndrome (MFS)National Institute of Health $unknownFeb. 1, 2008
Role of Fcgamma Receptor Polymorphisms in Determining IVIG Response in Kawasaki DiseaseThrasher FoundationJan. 1, 2008